American Society of Clinical Oncology
(ASCO) annual meeting kicked into high gear on Saturday. For investors, data presentations of note Saturday came from drugs developed by
ASCO itself held a media briefing this morning to discuss women's cancers, which will include data on
Avastin in ovarian cancer. This afternoon, ASCO held another press briefing at which previously unreleased results from a phase III study of
ruxolitinib in myelofibrosis will be released. These data followed Friday's presentation of early-stage data from
( YMI) competing myelofibrosis drug.
are all holding off-site investor events this evening.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.